AusCann Group Holdings Past Earnings Performance
Past criteria checks 0/6
AusCann Group Holdings's earnings have been declining at an average annual rate of -18.9%, while the Pharmaceuticals industry saw earnings growing at 1% annually. Revenues have been growing at an average rate of 23% per year.
Key information
-18.9%
Earnings growth rate
-9.1%
EPS growth rate
| Pharmaceuticals Industry Growth | 6.0% |
| Revenue growth rate | 23.0% |
| Return on equity | -132.4% |
| Net Margin | -693.8% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How AusCann Group Holdings makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 1 | -9 | 0 | 0 |
| 30 Sep 23 | 1 | -10 | 1 | 0 |
| 30 Jun 23 | 2 | -11 | 1 | 0 |
| 31 Dec 22 | 2 | -23 | 1 | 0 |
| 30 Sep 22 | 2 | -24 | 2 | 0 |
| 30 Jun 22 | 2 | -25 | 2 | 0 |
| 31 Mar 22 | 2 | -17 | 3 | 0 |
| 31 Dec 21 | 2 | -9 | 4 | 0 |
| 30 Sep 21 | 2 | -10 | 4 | 0 |
| 30 Jun 21 | 2 | -11 | 5 | 0 |
| 31 Dec 20 | 1 | -8 | 5 | -1 |
| 30 Sep 20 | 1 | -7 | 5 | 0 |
| 30 Jun 20 | 1 | -7 | 5 | 0 |
| 31 Mar 20 | 1 | -7 | 5 | 0 |
| 31 Dec 19 | 1 | -7 | 5 | 0 |
| 30 Sep 19 | 1 | -7 | 4 | 0 |
| 30 Jun 19 | 1 | -8 | 4 | 0 |
| 31 Mar 19 | 0 | -7 | 4 | 0 |
| 31 Dec 18 | 0 | -7 | 5 | 1 |
| 30 Sep 18 | 0 | -7 | 6 | 0 |
| 30 Jun 18 | 0 | -8 | 7 | 0 |
| 31 Mar 18 | 0 | -13 | 8 | 0 |
| 31 Dec 17 | 0 | -18 | 9 | 0 |
| 30 Sep 17 | 0 | -16 | 8 | 0 |
| 30 Jun 17 | 0 | -14 | 6 | 0 |
| 31 Mar 17 | 0 | -11 | 7 | 0 |
| 31 Dec 16 | 0 | -7 | 7 | 0 |
| 30 Sep 16 | 0 | -6 | 6 | 0 |
| 30 Jun 16 | 0 | -6 | 6 | 0 |
Quality Earnings: ACNN.F is currently unprofitable.
Growing Profit Margin: ACNN.F is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: ACNN.F is unprofitable, and losses have increased over the past 5 years at a rate of 18.9% per year.
Accelerating Growth: Unable to compare ACNN.F's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ACNN.F is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-13.2%).
Return on Equity
High ROE: ACNN.F has a negative Return on Equity (-132.42%), as it is currently unprofitable.